Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
2.340
-0.040 (-1.68%)
At close: Mar 24, 2026, 4:00 PM EDT
2.470
+0.130 (5.56%)
Pre-market: Mar 25, 2026, 4:43 AM EDT
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue (ttm)
796.97M EUR
Revenue Growth
+467.20%
P/S Ratio
0.94
Revenue / Employee
166,451 EUR
Employees
4,788
Market Cap
830.95M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 250.52M | 50.01% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 334.83M | 825.21% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| Tilray Brands | 837.32M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Esperion Therapeutics | 403.14M |
| Harrow | 272.30M |
EVO News
- 2 days ago - Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - Accesswire
- 6 days ago - Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Accesswire
- 13 days ago - Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 14 days ago - Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript - Seeking Alpha
- 14 days ago - Evotec Restructuring Aims To Improve Profitability After Transition Year - Benzinga
- 14 days ago - Evotec: What's Going On In 2026E And How To Value The Company - Seeking Alpha
- 2 months ago - Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Accesswire
- 2 months ago - Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Accesswire